William G. Hodge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William G. Hodge has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
David Barnes
4 shared publicationsAndra Morrison
3 shared publicationsElizabeth C. Lowcock
3 shared publicationsGabriela Lewin
3 shared publicationsHoward M. Schachter
3 shared publicationsKhai Tran
3 shared publications
Latest Publications
- Open Access
- 5 December 2012
- Published by Springer Nature
Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: a double-blinded, randomised clinical trial
- 5 December 2012
- Published by Springer Nature
Open AccessComparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: a double-blinded, randomised clinical trial
- 1 August 2008
- Published by Elsevier
- Vol. 43 (4) , 428-31
Tranexamic acid in the treatment of pediatric traumatic hyphema.
This study was undertaken to determine whether a difference exists in treatment outcome between patients treated with tranexamic acid (TEA) plus topical steroids and those treated with topical steroids alone. A retrospective cohort study was conducted to compare treatment results for children with traumatic hyphema treated with TEA and topical steroids versus topical steroids alone. Patients were identified from a chart review of the Children's Hospital of Eastern Ontario eye clinic and the Queen's Department of Ophthalmology emergency eye clinic for charts coded "traumatic hyphema." The primary outcomes measured included visual acuity, rebleed rate, intraocular pressure, and time to hyphema resolution. Covariates were hyphema grade, the need for medications to lower intraocular pressure, and the presence of associated ocular traumatic complications. Analysis was performed with both bivariate analysis and multivariate models. Two hundred and fifteen patients with traumatic hyphema were included in our study. One hundred and thirty-seven patients (63.1%) received TEA plus topical steroids, and the remaining 78 patients received topical steroids alone. There was no significant difference in rebleed rate between the TEA plus topical steroid group (1.6%) and the steroid-alone group (2.6%, p = 0.60). Patients with traumatic hyphema treated with TEA plus topical steroids did not have a significantly lower incidence of rebleed than those treated with topical steroids alone.
- 1 August 2008
- Published by Elsevier
- Vol. 43 (4) , 428-31
Tranexamic acid in the treatment of pediatric traumatic hyphema.
This study was undertaken to determine whether a difference exists in treatment outcome between patients treated with tranexamic acid (TEA) plus topical steroids and those treated with topical steroids alone. A retrospective cohort study was conducted to compare treatment results for children with traumatic hyphema treated with TEA and topical steroids versus topical steroids alone. Patients were identified from a chart review of the Children's Hospital of Eastern Ontario eye clinic and the Queen's Department of Ophthalmology emergency eye clinic for charts coded "traumatic hyphema." The primary outcomes measured included visual acuity, rebleed rate, intraocular pressure, and time to hyphema resolution. Covariates were hyphema grade, the need for medications to lower intraocular pressure, and the presence of associated ocular traumatic complications. Analysis was performed with both bivariate analysis and multivariate models. Two hundred and fifteen patients with traumatic hyphema were included in our study. One hundred and thirty-seven patients (63.1%) received TEA plus topical steroids, and the remaining 78 patients received topical steroids alone. There was no significant difference in rebleed rate between the TEA plus topical steroid group (1.6%) and the steroid-alone group (2.6%, p = 0.60). Patients with traumatic hyphema treated with TEA plus topical steroids did not have a significantly lower incidence of rebleed than those treated with topical steroids alone.
- 1 February 2008
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 43 (1) , 33-41
Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
- 1 February 2008
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 43 (1) , 33-41
Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
- 21 December 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 92 (1) , 7-12
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Aim: To systematically review the literature on the efficacy and harm of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in treating elevated intraocular pressure (IOP). Methods: Keywords were searched in major literature databases to identify relevant randomised clinical trials (RCTs) of PGAs for ophthalmic use. The study quality of RCTs was assessed using the Jadad scale. Outcomes assessed included reduction in IOP in individual patients, adverse events (AEs) and withdrawals due to AEs. Results: Eight unique RCTs evaluating a total of 1,722 individuals were included in this systematic review. Analysis did not show a significant reduction in the mean IOP from patients receiving latanoprost compared with those receiving brimonidine (WMD = −1.04; p = 0.30). On the other hand, the latanoprost group showed a significant reduction in mean IOP compared to the dorzolamide group (WMD = −2.64; pConclusion: Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was compared to dorzolamide or brimonidine in the present literature.
- 21 December 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 92 (1) , 7-12
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Aim: To systematically review the literature on the efficacy and harm of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in treating elevated intraocular pressure (IOP). Methods: Keywords were searched in major literature databases to identify relevant randomised clinical trials (RCTs) of PGAs for ophthalmic use. The study quality of RCTs was assessed using the Jadad scale. Outcomes assessed included reduction in IOP in individual patients, adverse events (AEs) and withdrawals due to AEs. Results: Eight unique RCTs evaluating a total of 1,722 individuals were included in this systematic review. Analysis did not show a significant reduction in the mean IOP from patients receiving latanoprost compared with those receiving brimonidine (WMD = −1.04; p = 0.30). On the other hand, the latanoprost group showed a significant reduction in mean IOP compared to the dorzolamide group (WMD = −2.64; pConclusion: Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was compared to dorzolamide or brimonidine in the present literature.
- Open Access
- 24 April 2007
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 176 (9) , 1285-1290
The consequences of waiting for cataract surgery: a systematic review
Background: Cataract surgery is the most common operative procedure performed in Canada, and how patients are affected by wait times for this surgery has important clinical, public health and health policy considerations. We conducted a systematic review to understand the relation between wait time for cataract surgery and patient outcomes and the variables that modify this relation. Methods: We performed an electronic search of 11 databases and the proceedings of 4 conferences. The search was restricted to studies published after the transition to phacoemulsification (1990). We assessed the quality of the included studies using the Jadad Scale for randomized controlled trials and the Newcastle–Ottawa Scale for cohort and case–control studies. The data were found to be inappropriate for meta-analysis, thus we performed a qualitative synthesis. Results: We found a total of 27 studies that met our inclusion criteria. When these studies were reviewed, a dichotomy was observed for the wait time–outcome relation: outcomes associated with wait times of ≤ 6 weeks were better than outcomes associated with wait times of ≥ 6 months. Patients who waited more than 6 months to receive cataract surgery experienced more vision loss, a reduced quality of life and had an increased rate of falls compared with patients who had wait times of less than 6 weeks. The outcomes associated with wait times between 6 weeks and 6 months remain unclear. Interpretation: Patients who wait more than 6 months for cataract surgery may experience negative outcomes during the wait period, including vision loss, a reduced quality of life and an increased rate of falls.
- 24 April 2007
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 176 (9) , 1285-1290
Open AccessThe consequences of waiting for cataract surgery: a systematic review
Background: Cataract surgery is the most common operative procedure performed in Canada, and how patients are affected by wait times for this surgery has important clinical, public health and health policy considerations. We conducted a systematic review to understand the relation between wait time for cataract surgery and patient outcomes and the variables that modify this relation. Methods: We performed an electronic search of 11 databases and the proceedings of 4 conferences. The search was restricted to studies published after the transition to phacoemulsification (1990). We assessed the quality of the included studies using the Jadad Scale for randomized controlled trials and the Newcastle–Ottawa Scale for cohort and case–control studies. The data were found to be inappropriate for meta-analysis, thus we performed a qualitative synthesis. Results: We found a total of 27 studies that met our inclusion criteria. When these studies were reviewed, a dichotomy was observed for the wait time–outcome relation: outcomes associated with wait times of ≤ 6 weeks were better than outcomes associated with wait times of ≥ 6 months. Patients who waited more than 6 months to receive cataract surgery experienced more vision loss, a reduced quality of life and had an increased rate of falls compared with patients who had wait times of less than 6 weeks. The outcomes associated with wait times between 6 weeks and 6 months remain unclear. Interpretation: Patients who wait more than 6 months for cataract surgery may experience negative outcomes during the wait period, including vision loss, a reduced quality of life and an increased rate of falls.
- 1 February 2007
- Published by Wolters Kluwer Health in Retina
- Vol. 27 (2) , 216-221
EVIDENCE FOR THE EFFECT OF Ω-3 FATTY ACIDS ON PROGRESSION OF AGE-RELATED MACULAR DEGENERATION
As part of a larger systematic review on the effect of ω-3 fatty acids on eye health, the aim of this report was to appraise and synthesize the evidence for the effects of ω-3 fatty acids in slowing down the progression of age-related macular degeneration (AMD) and/or decreasing the rate of progression to advanced forms of AMD. A comprehensive search was undertaken in six databases (MEDLINE, PreMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CAB Health, and Dissertation Abstracts). Two unique studies, one randomized clinical trial (RCT) and one prospective cohort study, satisfied the eligibility criteria and were included in the review. The RCT reported evidence on the effect of ω-3 fatty acids in slowing down the progression of AMD. The prospective cohort study addressed the question: what is the evidence that ω-3 fatty acids decrease the rate of progression to advanced forms of AMD? Clinical research on this topic is scarce. Only two studies were eligible to be included in this review. Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research.
- 1 February 2007
- Published by Wolters Kluwer Health in Retina
- Vol. 27 (2) , 216-221
EVIDENCE FOR THE EFFECT OF Ω-3 FATTY ACIDS ON PROGRESSION OF AGE-RELATED MACULAR DEGENERATION
As part of a larger systematic review on the effect of ω-3 fatty acids on eye health, the aim of this report was to appraise and synthesize the evidence for the effects of ω-3 fatty acids in slowing down the progression of age-related macular degeneration (AMD) and/or decreasing the rate of progression to advanced forms of AMD. A comprehensive search was undertaken in six databases (MEDLINE, PreMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CAB Health, and Dissertation Abstracts). Two unique studies, one randomized clinical trial (RCT) and one prospective cohort study, satisfied the eligibility criteria and were included in the review. The RCT reported evidence on the effect of ω-3 fatty acids in slowing down the progression of AMD. The prospective cohort study addressed the question: what is the evidence that ω-3 fatty acids decrease the rate of progression to advanced forms of AMD? Clinical research on this topic is scarce. Only two studies were eligible to be included in this review. Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research.
- 1 December 2006
- Published by Wolters Kluwer Health in Cornea
- Vol. 25 (10) , 1150-1152
Long-Term Efficacy of Phototherapeutic Keratectomy on Recurrent Corneal Erosion Syndrome
Purpose: To assess the long-term sequelae, principally time-to-first-recurrence, of phototherapeutic keratectomy (PTK) for the treatment of recurrent corneal erosion syndrome (RCES). Methods: A retrospective case series was performed. Thirty-nine eyes in 33 patients with RCES required PTK and were treated using the VISX STAR Excimer Laser System. The data were analyzed with the Kaplan-Meier survival estimate. Results: Patients were characterized by the cause of their RCES. More than 50% had epithelial corneal dystrophies, 31% were posttraumatic, and 15% were idiopathic. Overall, 25% of eyes had a recurrence by 3 months, and 36% had a recurrence by 9 months. The mean follow-up time was 17.4 months (range, 0.4-67.6 months). Of those who had a primary recurrence, 38% had a second and 15% had a third. Visual acuity was slightly decreased within 2 weeks after surgery, and 10% of patients developed transient haze. No serious adverse effects were reported. Conclusion: PTK is an important treatment of RCES refractory to other therapies. Long-term data suggest that most patients treated with PTK do not develop recurrences, and side effects from PTK are minimal.
- 1 December 2006
- Published by Wolters Kluwer Health in Cornea
- Vol. 25 (10) , 1150-1152
Long-Term Efficacy of Phototherapeutic Keratectomy on Recurrent Corneal Erosion Syndrome
Purpose: To assess the long-term sequelae, principally time-to-first-recurrence, of phototherapeutic keratectomy (PTK) for the treatment of recurrent corneal erosion syndrome (RCES). Methods: A retrospective case series was performed. Thirty-nine eyes in 33 patients with RCES required PTK and were treated using the VISX STAR Excimer Laser System. The data were analyzed with the Kaplan-Meier survival estimate. Results: Patients were characterized by the cause of their RCES. More than 50% had epithelial corneal dystrophies, 31% were posttraumatic, and 15% were idiopathic. Overall, 25% of eyes had a recurrence by 3 months, and 36% had a recurrence by 9 months. The mean follow-up time was 17.4 months (range, 0.4-67.6 months). Of those who had a primary recurrence, 38% had a second and 15% had a third. Visual acuity was slightly decreased within 2 weeks after surgery, and 10% of patients developed transient haze. No serious adverse effects were reported. Conclusion: PTK is an important treatment of RCES refractory to other therapies. Long-term data suggest that most patients treated with PTK do not develop recurrences, and side effects from PTK are minimal.
- 1 August 2006
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 41 (4) , 481-490
The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review
- 1 August 2006
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 41 (4) , 481-490
The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review
- 1 July 2006
- Published by Elsevier in Ophthalmology
- Vol. 113 (7) , 1165-1173
Efficacy of ω-3 Fatty Acids in Preventing Age-Related Macular Degeneration
- 1 July 2006
- Published by Elsevier in Ophthalmology
- Vol. 113 (7) , 1165-1173
Efficacy of ω-3 Fatty Acids in Preventing Age-Related Macular Degeneration
- 1 December 2005
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 40 (6) , 701-710
Iatrogenic risk factors for cytomegalovirus retinitis
- 1 December 2005
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 40 (6) , 701-710
Iatrogenic risk factors for cytomegalovirus retinitis